Benzinga··Globe NewswireAngelini Pharma Acquires Catalyst for $4.1B, Marking Bold U.S. Market Entry
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion in all-cash deal, marking entry into U.S. market and strengthening rare disease focus.
CPRXacquisitionM&A